Edgewise Therapeutics has transformed into a well-funded cardiovascular drug developer following the $1.55 billion sale of its muscular dystrophy drug sevasemten to Servier. Its lead cardiovascular candidate, EDG-7500, showed strong Phase 2 efficacy in treating both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM), with a favorable safety profile and simplified prescribing process. The company now has a cash runway extending into the early 2030s, allowing it to advance its late-stage pipeline without diluting shareholders, while retaining up to $1.1 billion in potential milestone payments. The outlook is bullish, pending successful Phase 3 trials validating the drug's differentiated biology and financial strength.
Analysts have raised their price targets for Cheniere Energy, signaling confidence in the company's future growth. Argus increased its target to $330, suggesting a 20.33% upside from the current price of around $274. TD Cowen also raised its target t...
KeyBanc and DA Davidson upgraded Duolingo's stock rating, citing positive sentiment and raising price targets to $137.11 and $160 respectively. This upgrade lifted Duolingo shares by 4.3% in pre-market trading to $135.71. Despite this optimism, most ...
ReNew Energy Global exceeded analyst expectations in Q1 FY2027 by reporting EPS of $0.17 versus $0.12 estimated and revenue of $506.4 million, surpassing the $459.86 million forecast. The company expanded its renewable energy portfolio to about 20.5 ...
Jack Henry & Associates is expected to report Q2 earnings with an EPS of $1.47 and revenue of $631.6 million. Analysts note the company has a strong record of beating earnings estimates, with an average surprise of nearly 20% in recent quarters. Fina...
Argenx reported successful Phase 3 clinical trial results for its drug VYVGART Hytrulo, targeting autoimmune myositis, especially benefiting patients with IMNM who lack approved therapies. The trial met its primary endpoint with statistically signifi...
